Who are PTV/r/OBV/DSV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elbasvir/Grazoprevir Fixed Dose Combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ptv-r-obv-dsv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

PTV/r/OBV/DSV — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PTV/r/OBV/DSV (PTV/r/OBV/DSV) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HCV direct-acting antiviral combination. Area: Infectious Disease / Virology.

marketed HCV direct-acting antiviral combination HCV NS3/4A protease, NS5A, NS5B polymerase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

PTV/r/OBV/DSV (PTV/r/OBV/DSV) — National Taiwan University Hospital. This is a fixed-dose combination of hepatitis C virus (HCV) protease and NS5A inhibitors that blocks viral replication by inhibiting essential nonstructural proteins.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PTV/r/OBV/DSV TARGET	PTV/r/OBV/DSV	National Taiwan University Hospital	marketed	HCV direct-acting antiviral combination	HCV NS3/4A protease, NS5A, NS5B polymerase
Elbasvir/Grazoprevir Fixed Dose Combination	Elbasvir/Grazoprevir Fixed Dose Combination	University Hospital, Clermont-Ferrand	phase 3	HCV direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HCV direct-acting antiviral combination class)

National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PTV/r/OBV/DSV — Competitive Intelligence Brief. https://druglandscape.com/ci/ptv-r-obv-dsv. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab